Management of hilar bile duct carcinoma

O. F. Bathe, J. T. Pacheco, P. B. Ossi, K. L. Hamilton, Dido Franceschi, Danny Sleeman, Joe Levi, Alan Livingstone

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background/Aims: Hilar cholangiocarcinoma is a rare tumor with a dismal prognosis. Because proximal bile duct cancers are uncommon, outcomes related to various therapeutic interventions are not well defined. Methodology: Between 1985 and 1997, 55 patients with bile duct cancers involving the proximal third of the extrahepatic bile ducts were seen. The management of patients with resectable and unresectable disease was retrospectively reviewed. All but four patients were followed until the time of death. Results: Forty patients underwent laparotomy following preoperative assessment of extent of disease and 19 patients (35%) ultimately underwent resection with curative intent. Survival was significantly longer in patients who underwent resection (2-year survival 47% vs. 18%; P=0.027). Of those patients whose disease was resected, 11 patients received adjuvant radiotherapy. Survival for this group was not significantly different from that seen in patients who did not receive adjuvant radiotherapy. Similarly, in patients with unresectable disease, administration of radiotherapy was not associated with an improved outcome. Conclusions: Locoregional extent of disease is the greatest problem in cases of proximal bile duct cancers. Resection provides the best hope for long-term survival, but new adjuvant strategies are needed.

Original languageEnglish
Pages (from-to)1289-1294
Number of pages6
JournalHepato-Gastroenterology
Volume48
Issue number41
StatePublished - Nov 9 2001
Externally publishedYes

Fingerprint

Bile Ducts
Carcinoma
Bile Duct Neoplasms
Adjuvant Radiotherapy
Survival
Klatskin Tumor
Extrahepatic Bile Ducts
Laparotomy
Radiotherapy

Keywords

  • Bile duct tumor
  • Cholangiocarcinoma
  • Outcome
  • Treatment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Bathe, O. F., Pacheco, J. T., Ossi, P. B., Hamilton, K. L., Franceschi, D., Sleeman, D., ... Livingstone, A. (2001). Management of hilar bile duct carcinoma. Hepato-Gastroenterology, 48(41), 1289-1294.

Management of hilar bile duct carcinoma. / Bathe, O. F.; Pacheco, J. T.; Ossi, P. B.; Hamilton, K. L.; Franceschi, Dido; Sleeman, Danny; Levi, Joe; Livingstone, Alan.

In: Hepato-Gastroenterology, Vol. 48, No. 41, 09.11.2001, p. 1289-1294.

Research output: Contribution to journalArticle

Bathe, OF, Pacheco, JT, Ossi, PB, Hamilton, KL, Franceschi, D, Sleeman, D, Levi, J & Livingstone, A 2001, 'Management of hilar bile duct carcinoma', Hepato-Gastroenterology, vol. 48, no. 41, pp. 1289-1294.
Bathe OF, Pacheco JT, Ossi PB, Hamilton KL, Franceschi D, Sleeman D et al. Management of hilar bile duct carcinoma. Hepato-Gastroenterology. 2001 Nov 9;48(41):1289-1294.
Bathe, O. F. ; Pacheco, J. T. ; Ossi, P. B. ; Hamilton, K. L. ; Franceschi, Dido ; Sleeman, Danny ; Levi, Joe ; Livingstone, Alan. / Management of hilar bile duct carcinoma. In: Hepato-Gastroenterology. 2001 ; Vol. 48, No. 41. pp. 1289-1294.
@article{38b6308d223845fd9f6b35da4ac3f33d,
title = "Management of hilar bile duct carcinoma",
abstract = "Background/Aims: Hilar cholangiocarcinoma is a rare tumor with a dismal prognosis. Because proximal bile duct cancers are uncommon, outcomes related to various therapeutic interventions are not well defined. Methodology: Between 1985 and 1997, 55 patients with bile duct cancers involving the proximal third of the extrahepatic bile ducts were seen. The management of patients with resectable and unresectable disease was retrospectively reviewed. All but four patients were followed until the time of death. Results: Forty patients underwent laparotomy following preoperative assessment of extent of disease and 19 patients (35{\%}) ultimately underwent resection with curative intent. Survival was significantly longer in patients who underwent resection (2-year survival 47{\%} vs. 18{\%}; P=0.027). Of those patients whose disease was resected, 11 patients received adjuvant radiotherapy. Survival for this group was not significantly different from that seen in patients who did not receive adjuvant radiotherapy. Similarly, in patients with unresectable disease, administration of radiotherapy was not associated with an improved outcome. Conclusions: Locoregional extent of disease is the greatest problem in cases of proximal bile duct cancers. Resection provides the best hope for long-term survival, but new adjuvant strategies are needed.",
keywords = "Bile duct tumor, Cholangiocarcinoma, Outcome, Treatment",
author = "Bathe, {O. F.} and Pacheco, {J. T.} and Ossi, {P. B.} and Hamilton, {K. L.} and Dido Franceschi and Danny Sleeman and Joe Levi and Alan Livingstone",
year = "2001",
month = "11",
day = "9",
language = "English",
volume = "48",
pages = "1289--1294",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "41",

}

TY - JOUR

T1 - Management of hilar bile duct carcinoma

AU - Bathe, O. F.

AU - Pacheco, J. T.

AU - Ossi, P. B.

AU - Hamilton, K. L.

AU - Franceschi, Dido

AU - Sleeman, Danny

AU - Levi, Joe

AU - Livingstone, Alan

PY - 2001/11/9

Y1 - 2001/11/9

N2 - Background/Aims: Hilar cholangiocarcinoma is a rare tumor with a dismal prognosis. Because proximal bile duct cancers are uncommon, outcomes related to various therapeutic interventions are not well defined. Methodology: Between 1985 and 1997, 55 patients with bile duct cancers involving the proximal third of the extrahepatic bile ducts were seen. The management of patients with resectable and unresectable disease was retrospectively reviewed. All but four patients were followed until the time of death. Results: Forty patients underwent laparotomy following preoperative assessment of extent of disease and 19 patients (35%) ultimately underwent resection with curative intent. Survival was significantly longer in patients who underwent resection (2-year survival 47% vs. 18%; P=0.027). Of those patients whose disease was resected, 11 patients received adjuvant radiotherapy. Survival for this group was not significantly different from that seen in patients who did not receive adjuvant radiotherapy. Similarly, in patients with unresectable disease, administration of radiotherapy was not associated with an improved outcome. Conclusions: Locoregional extent of disease is the greatest problem in cases of proximal bile duct cancers. Resection provides the best hope for long-term survival, but new adjuvant strategies are needed.

AB - Background/Aims: Hilar cholangiocarcinoma is a rare tumor with a dismal prognosis. Because proximal bile duct cancers are uncommon, outcomes related to various therapeutic interventions are not well defined. Methodology: Between 1985 and 1997, 55 patients with bile duct cancers involving the proximal third of the extrahepatic bile ducts were seen. The management of patients with resectable and unresectable disease was retrospectively reviewed. All but four patients were followed until the time of death. Results: Forty patients underwent laparotomy following preoperative assessment of extent of disease and 19 patients (35%) ultimately underwent resection with curative intent. Survival was significantly longer in patients who underwent resection (2-year survival 47% vs. 18%; P=0.027). Of those patients whose disease was resected, 11 patients received adjuvant radiotherapy. Survival for this group was not significantly different from that seen in patients who did not receive adjuvant radiotherapy. Similarly, in patients with unresectable disease, administration of radiotherapy was not associated with an improved outcome. Conclusions: Locoregional extent of disease is the greatest problem in cases of proximal bile duct cancers. Resection provides the best hope for long-term survival, but new adjuvant strategies are needed.

KW - Bile duct tumor

KW - Cholangiocarcinoma

KW - Outcome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0034781711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034781711&partnerID=8YFLogxK

M3 - Article

C2 - 11677948

AN - SCOPUS:0034781711

VL - 48

SP - 1289

EP - 1294

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 41

ER -